Effect of duloxetine on pain, function, and quality of life among patients with chemotherapy-induced painful peripheral neuropathy: a randomized clinical trial.

IMPORTANCE There are no known effective treatments for painful chemotherapy-induced peripheral neuropathy. OBJECTIVE To determine the effect of duloxetine, 60 mg daily, on average pain severity. DESIGN, SETTING, AND PATIENTS Randomized, double-blind, placebo-controlled crossover trial at 8 National Cancer Institute (NCI)-funded cooperative research networks that enrolled 231 patients who were 25 years or older being treated at community and academic settings between April 2008 and March 2011. Study follow-up was completed July 2012. Stratified by chemotherapeutic drug and comorbid pain risk, patients were randomized to receive either duloxetine followed by placebo or placebo followed by duloxetine. Eligibility required that patients have grade 1 or higher sensory neuropathy according to the NCI Common Terminology Criteria for Adverse Events and at least 4 on a scale of 0 to 10, representing average chemotherapy-induced pain, after paclitaxel, other taxane, or oxaliplatin treatment. INTERVENTIONS The initial treatment consisted of taking 1 capsule daily of either 30 mg of duloxetine or placebo for the first week and 2 capsules of either 30 mg of duloxetine or placebo daily for 4 additional weeks. MAIN OUTCOME MEASURES The primary hypothesis was that duloxetine would be more effective than placebo in decreasing chemotherapy-induced peripheral neuropathic pain. Pain severity was assessed using the Brief Pain Inventory-Short Form "average pain" item with 0 representing no pain and 10 representing as bad as can be imagined. RESULTS Individuals receiving duloxetine as their initial 5-week treatment reported a mean decrease in average pain of 1.06 (95% CI, 0.72-1.40) vs 0.34 (95% CI, 0.01-0.66) among those who received placebo (P = .003; effect size, 0.513). The observed mean difference in the average pain score between duloxetine and placebo was 0.73 (95% CI, 0.26-1.20). Fifty-nine percent of those initially receiving duloxetine vs 38% of those initially receiving placebo reported decreased pain of any amount. CONCLUSION AND RELEVANCE Among patients with painful chemotherapy-induced peripheral neuropathy, the use of duloxetine compared with placebo for 5 weeks resulted in a greater reduction in pain. TRIAL REGISTRATION clinicaltrials.gov Identifier: NCT00489411.

[1]  P. Masand,et al.  A 13-Week, Randomized Double-Blind, Placebo-Controlled, Cross-Over Trial of Ziprasidone in Bipolar Spectrum Disorder , 2015, Journal of clinical psychopharmacology.

[2]  M. Lacerenza,et al.  Painful Diabetic Polyneuropathy: Approach to Diagnosis and Management , 2012, The Clinical journal of pain.

[3]  G. Trifirò,et al.  Clinically Significant Drug Interactions with Newer Antidepressants , 2012, CNS Drugs.

[4]  S. Morales-Vidal,et al.  Diabetic Peripheral Neuropathy and the Management of Diabetic Peripheral Neuropathic Pain , 2012, Postgraduate medicine.

[5]  Eva L Feldman,et al.  Diabetic neuropathy: clinical manifestations and current treatments , 2012, The Lancet Neurology.

[6]  Y. Ohashi,et al.  Taxane-induced peripheral neuropathy and health-related quality of life in postoperative breast cancer patients undergoing adjuvant chemotherapy: N-SAS BC 02, a randomized clinical trial , 2012, Supportive Care in Cancer.

[7]  Guido Cavaletti,et al.  Chemotherapy-induced peripheral neurotoxicity (CIPN): an update. , 2012, Critical reviews in oncology/hematology.

[8]  Shung-Haur Yang,et al.  Duloxetine improves oxaliplatin-induced neuropathy in patients with colorectal cancer: an open-label pilot study , 2012, Supportive Care in Cancer.

[9]  J. Singleton,et al.  Diabetic Neuropathy , 2012, Continuum.

[10]  C. Fadul,et al.  Preliminary assessment of a neuropathic pain treatment and referral algorithm for patients with cancer. , 2011, Journal of pain and symptom management.

[11]  E. Kalso,et al.  Burden of chemotherapy-induced neuropathy—a cross-sectional study , 2011, Supportive Care in Cancer.

[12]  M. Hochberg,et al.  Duloxetine added to oral nonsteroidal anti-inflammatory drugs for treatment of knee pain due to osteoarthritis: results of a randomized, double-blind, placebo-controlled trial , 2011, Current medical research and opinion.

[13]  Guido Cavaletti,et al.  Chemotherapy‐induced peripheral neurotoxicity can be misdiagnosed by the National Cancer Institute Common Toxicity scale , 2011, Journal of the peripheral nervous system : JPNS.

[14]  F. Drago,et al.  Metabolic drug interactions between antidepressants and anticancer drugs: focus on selective serotonin reuptake inhibitors and hypericum extract. , 2011, Current drug metabolism.

[15]  J. England,et al.  Evidence‐based guideline: Treatment of painful diabetic neuropathy—report of the american association of neuromuscular and electrodiagnostic medicine, the american academy of neurology, and the american academy of physical medicine & rehabilitation , 2011, Muscle & nerve.

[16]  L. Arnold,et al.  Estimation of minimum clinically important difference for pain in fibromyalgia , 2011, Arthritis care & research.

[17]  C. Loprinzi,et al.  A double-blind, placebo-controlled trial of a topical treatment for chemotherapy-induced peripheral neuropathy: NCCTG trial N06CA , 2011, Supportive Care in Cancer.

[18]  E. Feldman,et al.  Evidence-based guideline: Treatment of painful diabetic neuropathy , 2011, Neurology.

[19]  P. Novotny,et al.  Natural history of paclitaxel-associated acute pain syndrome: prospective cohort study NCCTG N08C1. , 2011, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[20]  Jeffrey A. Cohen,et al.  The validity of neuropathy and neuropathic pain measures in patients with cancer receiving taxanes and platinums. , 2011, Oncology nursing forum.

[21]  A. Chakrabarti,et al.  A Comparative Evaluation of Amitriptyline and Duloxetine in Painful Diabetic Neuropathy , 2011, Diabetes Care.

[22]  L. Marangell,et al.  Comparative pain and mood effects in patients with comorbid fibromyalgia and major depressive disorder: Secondary analyses of four pooled randomized controlled trials of duloxetine , 2011, PAIN®.

[23]  D. Cornblath,et al.  Measures of chemotherapy‐induced peripheral neuropathy: a systematic review of psychometric properties , 2010, Journal of the peripheral nervous system : JPNS.

[24]  Cindy S Tofthagen.  Surviving chemotherapy for colon cancer and living with the consequences. , 2010, Journal of palliative medicine.

[25]  A. Crucitti,et al.  Safety and tolerability of duloxetine in the acute management of diabetic peripheral neuropathic pain: analysis of pooled data from three placebo-controlled clinical trials , 2010, Expert opinion on drug safety.

[26]  M. Detke,et al.  Efficacy and Safety of Duloxetine in Patients With Chronic Low Back Pain , 2010, Spine.

[27]  Richard E. White,et al.  Research design considerations for confirmatory chronic pain clinical trials: IMMPACT recommendations , 2010, PAIN®.

[28]  Jeffrey A. Cohen,et al.  The Reliability and Validity of a Modified Total Neuropathy Score-Reduced and Neuropathic Pain Severity Items When Used to Measure Chemotherapy-Induced Peripheral Neuropathy in Patients Receiving Taxanes and Platinums , 2010, Cancer nursing.

[29]  M. Dodd,et al.  The effect of symptom clusters on functional status and quality of life in women with breast cancer. , 2010, European journal of oncology nursing : the official journal of European Oncology Nursing Society.

[30]  E. Basch,et al.  The Brief Pain Inventory and its "pain at its worst in the last 24 hours" item: clinical trial endpoint considerations. , 2010, Pain medicine.

[31]  G. Cavaletti,et al.  Chemotherapy-Induced Peripheral Neurotoxicity assessment: a critical revision of the currently available tools. , 2010, European journal of cancer.

[32]  R. Bennett,et al.  Duloxetine, a centrally acting analgesic, in the treatment of patients with osteoarthritis knee pain: A 13-week, randomized, placebo-controlled trial , 2009, PAIN.

[33]  J. Farrar,et al.  Interpreting the clinical importance of group differences in chronic pain clinical trials: IMMPACT recommendations , 2009, PAIN.

[34]  Sudhakar Tummala,et al.  NCCN task force report: management of neuropathy in cancer. , 2009, Journal of the National Comprehensive Cancer Network : JNCCN.

[35]  Y. Ohashi,et al.  Prospective assessment of chemotherapy-induced peripheral neuropathy due to weekly paclitaxel in patients with advanced or metastatic breast cancer (CSP-HOR 02 study) , 2009, Supportive Care in Cancer.

[36]  E. Kalso,et al.  Amitriptyline in the prevention of chemotherapy-induced neuropathic symptoms. , 2009, Anticancer research.

[37]  J. Paul,et al.  An Assessment of Drug-Drug Interactions: The Effect of Desvenlafaxine and Duloxetine on the Pharmacokinetics of the CYP2D6 Probe Desipramine in Healthy Subjects , 2008, Drug Metabolism And Disposition.

[38]  G. Y. Wong,et al.  Efficacy of lamotrigine in the management of chemotherapy‐induced peripheral neuropathy , 2008, Cancer.

[39]  M. Detke,et al.  Efficacy and safety of duloxetine for treatment of fibromyalgia in patients with or without major depressive disorder: Results from a 6-month, randomized, double-blind, placebo-controlled, fixed-dose trial , 2008, PAIN.

[40]  David Cella,et al.  Interpreting the clinical importance of treatment outcomes in chronic pain clinical trials: IMMPACT recommendations. , 2008, The journal of pain : official journal of the American Pain Society.

[41]  G. Y. Wong,et al.  Efficacy of gabapentin in the management of chemotherapy‐induced peripheral neuropathy , 2007, Cancer.

[42]  M. Bakitas.  Background Noise: The Experience of Chemotherapy-Induced Peripheral Neuropathy , 2007, Nursing research.

[43]  D. Greenblatt,et al.  Comparison of Duloxetine, Escitalopram, and Sertraline Effects on Cytochrome P450 2D6 Function in Healthy Volunteers , 2007, Journal of clinical psychopharmacology.

[44]  J. Wernicke,et al.  A randomized controlled trial of duloxetine in diabetic peripheral neuropathic pain , 2006, Neurology.

[45]  D. Cella,et al.  Validation and reduction of FACT/GOG-Ntx subscale for platinum/paclitaxel-induced neurologic symptoms: a gynecologic oncology group study , 2006, International Journal of Gynecologic Cancer.

[46]  D. Goldstein,et al.  Duloxetine for patients with diabetic peripheral neuropathic pain: a 6-month open-label safety study. , 2006, Pain medicine.

[47]  B. Mccarberg,et al.  Duloxetine for the management of diabetic peripheral neuropathic pain: response profile. , 2006, Pain medicine.

[48]  C. Glueck,et al.  Interaction of duloxetine and warfarin causing severe elevation of international normalized ratio. , 2006, JAMA.

[49]  Muriel Viala,et al.  Descriptive and prognostic value of patient-reported outcomes: the bortezomib experience in relapsed and refractory multiple myeloma. , 2006, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[50]  Smriti Iyengar,et al.  A double-blind, randomized multicenter trial comparing duloxetine with placebo in the management of diabetic peripheral neuropathic pain. , 2005, Pain medicine.

[51]  M. Detke,et al.  Duloxetine vs. placebo in patients with painful diabetic neuropathy , 2005, Pain.

[52]  David A. Flockhart,et al.  CYP2D6 genotype, antidepressant use, and tamoxifen metabolism during adjuvant breast cancer treatment. , 2005, Journal of the National Cancer Institute.

[53]  S. Wise,et al.  Effect of duloxetine on tolterodine pharmacokinetics in healthy volunteers. , 2004, British journal of clinical pharmacology.

[54]  M. Jensen,et al.  Validation of the Brief Pain Inventory for chronic nonmalignant pain. , 2004, The journal of pain : official journal of the American Pain Society.

[55]  D. Fishman,et al.  Psychometric evaluation of the Functional Assessment of Cancer Therapy/Gynecologic Oncology Group—Neurotoxicity (Fact/GOG‐Ntx) questionnaire for patients receiving systemic chemotherapy , 2003, International journal of gynecological cancer : official journal of the International Gynecological Cancer Society.

[56]  D. Fishman,et al.  Psychometric evaluation of the Functional Assessment of Cancer Therapy/Gynecologic Oncology Group—Neurotoxicity (Fact/GOG-Ntx) questionnaire for patients receiving systemic chemotherapy , 2003, International Journal of Gynecologic Cancer.

[57]  G. Norman,et al.  Interpretation of Changes in Health-related Quality of Life: The Remarkable Universality of Half a Standard Deviation , 2003, Medical care.

[58]  S. Reddy,et al.  Duloxetine is both an inhibitor and a substrate of cytochrome P4502D6 in healthy volunteers , 2003, Clinical pharmacology and therapeutics.

[59]  D. Cella,et al.  Combining anchor and distribution-based methods to derive minimal clinically important differences on the Functional Assessment of Cancer Therapy (FACT) anemia and fatigue scales. , 2002, Journal of pain and symptom management.

[60]  P. Novotny,et al.  Phase III evaluation of nortriptyline for alleviation of symptoms of cis-platinum-induced peripheral neuropathy , 2002, Pain.

[61]  D. Cella,et al.  What is a clinically meaningful change on the Functional Assessment of Cancer Therapy-Lung (FACT-L) Questionnaire? Results from Eastern Cooperative Oncology Group (ECOG) Study 5592. , 2002, Journal of clinical epidemiology.

[62]  J. Farrar,et al.  Clinical importance of changes in chronic pain intensity measured on an 11-point numerical pain rating scale , 2001, PAIN.

[63]  J. Heimans,et al.  Pitfalls in grading severity of chemotherapy-induced peripheral neuropathy. , 1998, Annals of oncology : official journal of the European Society for Medical Oncology.

[64]  C. Cleeland,et al.  Pain assessment: global use of the Brief Pain Inventory. , 1994, Annals of the Academy of Medicine, Singapore.

[65]  P. Lachenbruch.  Statistical Power Analysis for the Behavioral Sciences (2nd ed.) , 1989 .

[66]  Jacques P. Brown,et al.  A Double‐blind, Randomized, Placebo‐controlled Study of the Efficacy and Safety of Duloxetine for the Treatment of Chronic Pain Due to Osteoarthritis of the Knee , 2011, Pain practice : the official journal of World Institute of Pain.

[67]  C. Cleeland.  The Brief Pain Inventory User Guide , 2009 .

[68]  M. Rowbotham,et al.  Duloxetine for the management of diabetic peripheral neuropathic pain: evidence-based findings from post hoc analysis of three multicenter, randomized, double-blind, placebo-controlled, parallel-group studies. , 2007, Clinical therapeutics.

[69]  P. Wiffen,et al.  Antidepressants for neuropathic pain. , 2005, The Cochrane database of systematic reviews.

[70]  W. Willis,et al.  Neuroanatomy of the pain system and of the pathways that modulate pain. , 1997, Journal of clinical neurophysiology : official publication of the American Electroencephalographic Society.